NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
7.53
+0.31 (4.29%)
May 27, 2025, 3:43 PM - Market open
Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors.
The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
NeOnc Technologies Holdings, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas Chen |
Contact Details
Address: 23975 Park Sorrento, Suite 205 Calabasas, California 91302 United States | |
| Phone | 310-663-7831 |
| Website | neonctech.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Executive Officer, Chief Scientific Officer and Director |
| Keithly A. Garnett | Chief Financial Officer and Director |
| Patrick Walters CPA | Chief Operating Officer |
| Amir Farrokh Heshmatpour | President, Executive Chairman and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | EFFECT | Notice of Effectiveness |
| May 6, 2025 | 424B5 | Filing |
| Apr 29, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 25, 2025 | SCHEDULE 13D | Filing |
| Apr 11, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |